Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study

The Lancet 2026 Open access

Read full text
Authors: Lars H. Lund, Arantxa Barandiarán Aizpurua, Entela Bollano, Oscar Braun, Jan Leendert P Brouwer, Jan W Buikema, Antonio Cannata, Roy S. Gardner, M Louis Handoko, Chim Choy Lang, Marco Metra, Gianfranco Sinagra
+18 more Tonje Thorvaldsen, Robert M A van der Boon, Bart J. van Essen, Sanjiv J Shah, Adriaan A Voors, Carolyn S P Lam, Bertram Pitt, Scott D Solomon, Camilla Hage, Marcus Ståhlberg, Alberto Bernareggi, A D Gordon, Marianna Del Sole, Elin Rosendahl, Patrik Stromberg, Göran Westerberg, Robert Edfors, Mark Colquhoun Petrie
DOI: 10.1016/s0140-6736(26)00904-9
Cited by: 1
References: 28

Fields of Study & Subjects

Regulation of Appetite and Obesity Diabetes Treatment and Management Apelin-related biomedical research

Publication details

Journal / source
The Lancet
Publisher
Elsevier BV
Volume
408
Issue
10551
Pages
248–262
Publication date
24 June 2026
Language
EN